Reading list
Ipamorelin reading list
The surgical trial is the paper I’d start with. Its practical ambition gives the earlier laboratory work a different perspective.
Suggested starting points
Begin with the randomized bowel-resection trial, then turn back to ipamorelin’s founding characterization and the healthy-male-volunteer study. That sequence moves from the clinical question to the selective hormone response.
The animal papers on skeletal mineral content and cisplatin-associated weight loss in ferrets are especially useful companions. The cardiovascular paper concerns a different ghrelin-receptor agonist in rats. The ghrelin review supplies class context, and the later reviews offer broader safety assessments.
- Ipamorelin, the first selective growth hormone secretagogue ↗
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers ↗
- Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus ↗
- Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients ↗
- Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats ↗
- The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats ↗
- The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism ↗
- Integrated approach to early detection of cardiovascular toxicity induced by a ghrelin receptor agonist ↗
- Therapeutic peptides in gerontology: mechanisms and applications for healthy aging ↗
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance ↗
- Actions and therapeutic pathways of ghrelin for gastrointestinal disorders ↗